REGULATORY

Expert Panel Talks over Yakkasa, Revamp of Price Revision Method; Fixed Margin, Claw-Back Mooted

By Yoshinori Sagehashi March 20, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s current drug price revision mechanism inevitably creates a gap between an NHI price and a market price, called yakkasa, which has effectively become a source of revenue particularly for pharmacies. Many members of a key health ministry expert panel…

To read the full story

Expert Panel Discusses 2% Buffer Zone, Member Floats “Regional Index”
March 20, 2023
Expert Panel Seeks Revision of Drug Pricing Rules to Stabilize Supplies
March 20, 2023

REGULATORY

PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
10 Firms Win Approval for Bilanoa Generics, 2 Contenders for Fycompa
February 17, 2026
MHLW to Brand OTC-Like Drug Cost Rule as “Partially Non-Insured Care”
February 17, 2026
Taiyo Pharma’s Propranolol Designated as Drug for Specific Use
February 17, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…